The small molecule TGFβ inhibitor Galunisertib has been tested in several clinical trials in patients with cancer, either alone or in combination with Lomustine or anti-PDL-1 with close to 50% experiencing treatment-related adverse effects [63, 64]. Here, TGFB1 is linked to cancer.